Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, October 8, 2009 - Flublok


Submission Type: Original Application   Submission ID:  125285/0   Office: OVRR  
Influenza Vaccine
Protein Sciences Corporation          
Telecon Date/Time:  08-OCT-2009 10:11 AM             Initiated by FDA?  No
Telephone Number:    
Communication Categorie(s):
Telecon Summary:
Response to CBER's October 6, 2009 Information Request for clarification of details of September 24, 2009 face-to-face meeting.
FDA Participants:  
Timothy Fritz
Non-FDA Participants:   
Penny Post
Trans-BLA Group: No
Related STNs:  None
Related PMCs:  None
Telecon Body:
Hi Tim,
Below are the answers to your questions regarding the September 24 BLA meeting:
1)  The attendees from BARDA were:  Dr. Maurice Harmon and Dr. Frank Arnold
2)  Comment 1t:  We indicated that we would set an upper specification on –b(4)--------------------- taking into account assay variability and strain specific trends . –b(4)------------------- over the specification would be investigated.
3)  Comment 1w:   We do not recall stating that 3 lots would be used to complete container closure integrity testing for shipping.  We feel that one lot with 3 shippers tested would be adequate.
4)  Peter Cardinal's title is:  Director, Validation 
Feel free to contact me if you have any other questions.
Penny L. Post, PhD
Vice President, Regulatory and Quality
Protein Sciences Corporation
1000 Research Parkway
Meriden, CT  06450
Phone:  203-599-6064 X156
FAX:     203-599-6069

Page Last Updated: 02/15/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English